Xeltis has raised EURO 27 million (USD 34 million/CHF 32 million) in an oversubscribed Series B financing.
Life Sciences Partners, and Kurma Partners led the round, with participation from VI Partners, and current shareholders of Xeltis.
The financing will primarily be used to fund market access activities for the company’s first product, a pulmonary valve, and the development of the company’s product pipeline.
The replacement pulmonary valve will be used to treat the orphan pediatric indication of severe congenital malformations of the heart.
For further deal information visit Current Agreements (subscription required)
Report: Top 50 Big Biotech Partnering and M&A Deal Trends